Nuveen’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Nuveen’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-81,898	Closed	-$332K	–	3329
2023 Q4	$332K	Hold	81,898	–	–	﹤0.01%	3127
2023 Q3	$780K	Sell	81,898 -580	-0.7%	-$2.27K	﹤0.01%	2678
2023 Q2	$770K	Buy	82,478 +60,629	+277%	+$597K	﹤0.01%	2770
2023 Q1	$194K	Hold	21,849	–	–	﹤0.01%	2991
2022 Q4	$109K	Sell	21,849 -14,787	-40%	-$86.6K	﹤0.01%	3104
2022 Q3	$212K	Buy	36,636 +4,918	+16%	+$34.8K	﹤0.01%	3107
2022 Q2	$175K	Buy	31,718 +14,224	+81%	+$117K	﹤0.01%	3158
2022 Q1	$202K	Hold	17,494	–	–	﹤0.01%	3193
2021 Q4	$222K	Buy	+17,494	New	+$264K	﹤0.01%	3225

Nuveen's THRX Position: Q1 2024 in Review

Nuveen sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 81,898 shares — an estimated $332K sold.

Nuveen first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $780K in Q3 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

Nuveen reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Nuveen sold 81,898 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $332K.
Nuveen first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Nuveen's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $780K in Q3 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Nuveen's 13F filing for Q1 2024, filed 13 May 2024.